
PR02 PMEPA1 has an oncogenic role in the context of TGF-β signaling in hepatocellular carcinoma. Marta Piqué-Gili. Icahn School of Medicine at Mount Sinai, New York, NY, United States.


PR04 CRISPR lipid nanoparticle modulates the tumor immune microenvironment of liver metastases by genetically eliminating M2 polarization pathway in macrophages. Tyler Galbraith. Houston Methodist Research Institute, Houston, TX, United States.

PR05 A novel kinase inhibitor for B-catenin mutant hepatocellular carcinoma. Alexander Rialdi. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

PR06 Identifying regulatory transcription factors in primary liver cancer cell lineage commitment using single cell ATAC sequencing. Amanda J. Craig. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.